Case series, such as Richards et al., also reported decreased AUD symptoms based on alcohol use disorder identification test score in patients receiving Semaglutide for weight loss, further corroborating the potential of GLP-1RAs across formulations [40]
Most symptoms are mild to moderate and improve significantly within 4-8 weeks of starting treatment or after dose adjustments
I built this matrix by mapping each row to the single trial endpoint that produced the highest-quality primary evidence as of mid-2026: percent body-weight change for efficacy (Jastreboff 2023, SURMOUNT-1, STEP 1), three-point MACE for cardiovascular (SELECT), MRI-PDFF for hepatic fat (retatrutide Phase 2 sub-analyses, [unverified primary source]), and treatment-emergent adverse event rates for GI burden
With fresh approvals, mounting clinical evidence, and a surge in adoption by specialists far beyond endocrinology, these treatments are rewriting the rules for managing comorbid conditions and reshaping adjacent markets
